Streptokinase and reduced plasma viscosity: a second benefit.

The purpose of this pilot study on a small cohort of patients (n = 13) with acute myocardial infarction receiving systemic streptokinase (STK) thrombolytic therapy was to measure the decrease in plasma viscosity concomitant with fibrinogen depletion. The treatment group was compared with a similar control group not given thrombolytic therapy. Serial relevant blood studies were undertaken in both groups for a period of 6 d.

The effects of cyclosidimine, a peripheral vasodilator drug, on blood pressure and heart rate in healthy subjects.

Cyclosidimine is a new vasodilator drug with a direct action on vascular smooth muscle. Oral administration of 2.5, 5.

Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, sotalol, and metoprolol.

Beta adrenoceptor blockers differ mainly in their plasma elimination half-lives (t 1/2 s). It has been assumed that drugs with longer t 1/2 will have a longer duration of effect on exercise tachycardia. Several factors may influence the duration of action of beta blockers; we have investigated the contribution of plasma elimination t 1/2 and dose by comparing the effects on an exercise tachycardia in healthy subjects of placebo, 25, 50, 100, and 200 mg of atenolol and of sotalol, and 50, 100, 200, and 400 mg metoprolol.

Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug.

1 Observations were made in five subjects who exercised before and at 2, 3, 6, 8, 24, 33 and 48 h after the oral administration of placebo and 5, 10, 20 and 40 mg betaxolol. 2 The exercise heart rate remained constant at all times after the placebo. All doses of betaxolol significantly reduced the exercise tachycardia at all times.

Comparison of propranolol and inderal L.A. in patients with angina.

TWELVE patients with moderately severe angina pectoris completed a double blind cross-over comparison of conventional propranolol (40 mg q.i.d.